Bexotegrast (PLN-74809)
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Pliant Therapeutics
Pliant Therapeutics is pioneering a new approach to treating fibrotic diseases by targeting the biological pathways that drive fibrosis, specifically through integrin-mediated activation of TGF-β. The company's most advanced program, bexotegrast, has demonstrated promising safety and efficacy signals in mid-stage clinical trials for IPF and PSC, positioning it as a potential first-in-class oral therapy. With a robust pipeline of integrin-targeted candidates and a strong intellectual property position, Pliant aims to address the substantial market opportunity in fibrotic diseases, which currently lack effective anti-fibrotic treatments.
View full company profileAbout Pliant Therapeutics
Pliant Therapeutics is pioneering a new approach to treating fibrotic diseases by targeting the biological pathways that drive fibrosis, specifically through integrin-mediated activation of TGF-β. The company's most advanced program, bexotegrast, has demonstrated promising safety and efficacy signals in mid-stage clinical trials for IPF and PSC, positioning it as a potential first-in-class oral therapy. With a robust pipeline of integrin-targeted candidates and a strong intellectual property position, Pliant aims to address the substantial market opportunity in fibrotic diseases, which currently lack effective anti-fibrotic treatments.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Axatilimab (SNDX-6352) | Syndax Pharmaceuticals | Phase 2 |
| PIPE-791 | Contineum Therapeutics | Phase 1 |
| LYT-100 (Deupirfenidone) | PureTech Health | Phase 2b |